ALLMedicine™ Acquired Hemophilia Center

Apr 21st, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Hematological malignancies, especially lymphoid malignancies, are known to be underlying causes of AHA; however, thus far, there is no re...

Mar 30th, 2021 - Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory ...

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|

Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

Apr 1st, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

Apr 26th, 2021 - OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is a recombinant DNA derived, antihemophilic factor indicated for the on-demand treatment and control of bleeding episodes in adults with acquired hemophilia A. OBIZUR, Antihemophilic ...

Apr 21st, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Hematological malignancies, especially lymphoid malignancies, are known to be underlying causes of AHA; however, thus far, there is no re...

Mar 30th, 2021 - Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory ...

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|

Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

Jan 8th, 2018 - LONDON (Reuters) - Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance...